Pharmacokinetics of Oseltamivir Carboxylate In Morbidly Obese Subjects

Completed · Phase 1/Phase 2

Conditions studied: Obesity

In brief

One in three Americans are obese. Obese subjects may or may not need higher doses of the anti-flu drug known as Tamiflu (oseltamivir). The current study is being done to see if the FDA approved dose of oseltamivir will achieve similar concentrations in obese healthy volunteers compared to that previously shown in non-obese volunteers.

Key facts

Study ID
NCT01179919
Run by
Manjunath Prakash Pai
People needed
21
Starts
2010-07-01
Expected to finish
2010-12-01
Last updated by the study team
2017-02-09

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.